Exagen Diagnostics Filed, US Offering, Removed, Nasdaq: EXDX

Sells diagnostic blood tests that detect lupus and rheumatoid arthritis.

Industry: Health Care

Latest Trade: ()

First Day Return:

Return from IPO:

Industry: Health Care

We are a commercial-stage diagnostics company committed to addressing the significant unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. These chronic diseases can cause lifelong inflammation in the joints, tissues and internal organs, resulting in serious complications, such as irreversible organ damage. The accurate, timely and differential diagnosis for patients suffering from the approximately 30 autoimmune rheumatic diseases is critical as treatment for each disease can vary, and inappropriate or delayed therapy may expose patients to unnecessary risks or the hazards of uncontrolled disease activity. We currently market five products under our Avise brand to provide an accurate, timely and differential diagnosis and to optimize the treatment of ARDs.
more less
IPO News for Exagen Diagnostics
more
IPO Data
IPO File Date 09/19/2014
Offer Price
Price Range n/a
Offer Shares (mm) n/a
Deal Size ($mm) $69
IPO Data
IPO Date
Offer Price
Price Range n/a
Offer Shares (mm) n/a
Deal Size ($mm) $69
Underwriters
more
Company Data
Headquarters Vista, CA
Founded 2002
Employees 107
Website www.exagen.com